PET Imaging of PARP with with [18F]olaparib".
Poly (ADP‐ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, and dose optimization of novel PARP‐targeting agents.
We have synthesised the fluorine-18 radiolabelled version of olaparib, an FDA-approved PARP inhibitor, and tested it in vitro and in vivo with promising results, and are now moving the first steps towards the clinical evaluation of this novel imaging agent.
20 November 2018, 13:30 (Tuesday, 7th week, Michaelmas 2018)
Old Road Campus Research Building, Headington OX3 7DQ
Room 71a, b & c
Anna Pacelli (University of Oxford)
Department of Oncology
Anne-Marie Honeyman-Tafa (University of Oxford)
Organiser contact email address:
Dr Bart Cornelissen (University of Oxford)
CRUK & EPSRC Cancer Imaging Centre in Oxford
members of the CICO community and interested parties in the University or NHS